Preparation of curcumin-hydroxypropyl-β-cyclodextrin inclusion complex by cosolvency-lyophilization procedure to enhance oral bioavailability of the drug

References

• Matloob AH, Mourtas S, Klepetsanis P. Increasing the stability of curcumin in serum with liposomes or hybrid drug-in-cyclodextrin-in-liposome systems: A comparative study. Int J Pharm. 2014;476:108–115.
   PubMed Web of Science ®Google Scholar
• Chaurasia S, Chaubey P, Patel RR, et al. Curcumin-polymeric nanoparticles against colon-26 tumor-bearing mice: cytotoxicity, pharmacokinetic and anticancer efficacy studies. Drug Dev Ind Pharm. 2016;42:694–700.
   PubMed Web of Science ®Google Scholar
• Shehzad A, Lee J, Lee YS. Curcumin in various cancers. Biofactors. 2013;39:56–68.
   PubMed Web of Science ®Google Scholar
• Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10
   PubMedGoogle Scholar
• Cheng AL, Hsu CH, Lin JK. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–2900.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lu CT, Li WF, et al. Physical characterization and cellular uptake of propylene glycol liposomes in vitro. Drug Dev Ind Pharm. 2012;38:365–371.
   PubMed Web of Science ®Google Scholar
• Wang LL, He DD, Wang SX, et al. Preparation and evaluation of Curcumin-loaded self-assembled micelles. Drug Dev Ind Pharm. 2017;44:563–569.
   PubMed Web of Science ®Google Scholar
• Rachmawati H, Budiputra DK, Mauludin R. Curcumin nanoemulsion for transdermal application: formulation and evaluation. Drug Dev Ind Pharm. 2015;41:560–566.
   PubMed Web of Science ®Google Scholar
• Wang T, Wang N, Song H, et al. Preparation of anhydrous reverse micelle delivery systems to enhance oral bioavailability and antidiabetic efficacy of berberine. Eur J Pharm Sci. 2011;44:127–135.
   PubMed Web of Science ®Google Scholar
• Wang T, Zhen YY, Ma XY, et al. Phospholipid bilayer-coated aluminum nanoparticles as an effective vaccine adjuvant-delivery system. ACS Appl Mater Interfaces. 2015;7:6391–6396.
   PubMed Web of Science ®Google Scholar
• Elbayoumi TA, Torchilin VP. Current trends in liposome research. Methods Mol Biol. 2010;605:1–27.
   PubMedGoogle Scholar
• Yokoyama M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv. 2010;7:145–158.
   PubMed Web of Science ®Google Scholar
• ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665–685.
   PubMed Web of Science ®Google Scholar
• Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev. 1998;98:1743–1753.
   PubMed Web of Science ®Google Scholar
• Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004;3:1023–1035.
   PubMed Web of Science ®Google Scholar
• Valle EMMD. Cyclodextrins and their uses: a review. Process Biochen.2004;39:1033–1046.
   Web of Science ®Google Scholar
• Sagiraju S, Jursic BS. NMR spectroscopic study of cyclodextrin inclusion complexes with A-007 prodrugs. Carbohydr Res. 2008;343:1180–1190.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329:1–11.
   PubMed Web of Science ®Google Scholar
• Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86:147–162.
   PubMed Web of Science ®Google Scholar
• Gould S, Scott RC. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005;43:1451–1459.
   PubMed Web of Science ®Google Scholar
• Granero GE, Maitre MM, Garnero C, et al. Synthesis, characterization and in vitro release studies of a new acetazolamine-HP-β-CD-TEA inclusion complex. Eur J Med Chem. 2008;43:464–470.
   PubMed Web of Science ®Google Scholar
• Szente L, Szejtli J. Highly soluble cyclodextrin derivatives: Chemistry, properties, and trends in development. Adv Drug Deliver Rev. 1999;36:17–28.
   PubMed Web of Science ®Google Scholar
• Choi HG, Kim DD, Jun HW, et al. Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-beta-cyclodextrin. Drug Dev Ind Pharm. 2003;29:1085–1094.
   PubMed Web of Science ®Google Scholar
• Wang N, Wang T, Wang ML, et al. Using ultrafiltration to facilitate simultaneous quantification of 5-fluorouracil in mouse plasma and tissues by HPLC. J Liq Chromatogr Relat Technol. 2011;34:2033–2047.
   Web of Science ®Google Scholar
• Wang T, Wang N, Zhang Y, et al. Solvent injection-lyophilization of tert-butyl alcohol/water cosolvent systems to prepare drug-loading solid lipid nanoparticles. Colloids and Surfaces B: Biointerfaces. 2010;79:254–261.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Connors KA. Phase solubility techniques. Adv Chem Instrum. 1965;4:117–212.
   Google Scholar
• Ge X, Huang Z, Tian S, et al. Complexation of carbendazim with hydroxypropyl-β-cyclodextrin to improve solubility and fungicidal activity. Carbohydr Polym. 2012;89:208–212.
   PubMed Web of Science ®Google Scholar
• Jun SW, Kim MS, Kim JS, et al. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2007;66:413–421.
   PubMed Web of Science ®Google Scholar
• Mohan PRK, Sreelakshmi G, Muraleedharan CV, et al. Water soluble complexes of curcumin with cyclodextrins: characterization by FT-Raman spectroscopy. Vib Spectrosc. 2012;62:77–84.
   Web of Science ®Google Scholar
• Patel NA, Patel NJ, Patel RP. Design and evaluation of transdermal drug delivery system for curcumin as an anti-inflammatory drug. Drug Dev Ind Pharm. 2009;35:234–242.
   PubMed Web of Science ®Google Scholar
• Eid EEM, Abdul AB, Suliman FEO, et al. Characterization of the inclusion complex of zerumbone with hydroxypropyl-β-cyclodextrin. Carbohyd Polym. 2011; 83:1707–1714.
   Web of Science ®Google Scholar
• Chen W, Yang LJ, Ma SX, et al. cyclodextrin host–guest system: preparation, characterization, inclusion mode, solubilization and stability. Carbohyd Polym. 2011;84:1321–1328.
   Web of Science ®Google Scholar
• Liu L, Zhu S. Preparation and characterization of inclusion complexes of prazosin hydrochloride with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin. J Pharm Biomed Anal. 2006;40:122–127.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhang T, Tao J, et al. Preparation, characterization, and pharmacokinetics of the inclusion complex of genipin-beta-cyclodextrin. Drug Dev Ind Pharm. 2009;35:1452–1459.
   PubMed Web of Science ®Google Scholar
• Marques HMC, Hadgraft JW, Kellaway I. Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int J Pharmaceut. 1990;63:259–266.
   Web of Science ®Google Scholar
• Semcheddine F, Guissi NI, Liu X, et al. Effects of the preparation method on the formation of true nimodipine SBE-β-CD/HP-β-CD inclusion complexes and their dissolution rates enhancement. AAPS PharmSci Tech. 2015;16:704–715.
   PubMed Web of Science ®Google Scholar
• He Z, Zhong D, Chen X, et al. Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation. Eur J Pharm Sci. 2004;21:487–491.
   PubMed Web of Science ®Google Scholar
• Thompson DO. Cyclodextrins-enabling excipients: their present and future use in Pharmaceuticals. Crit Rev Ther Drug Carrier Syst. 1997;14:1–104.
   PubMed Web of Science ®Google Scholar
• de Freitas MR, Rolim LA, Soares MF, et al. Inclusion complex of methyl-β-cyclodextrin and olanzapine as potential drug delivery system for schizophrenia. Carbohydr Polym. 2012; 89:1095–1100.
   PubMed Web of Science ®Google Scholar
• Guo B, Zhong S, Li N, et al. Dissolution enhancement of cefdinir with hydroxypropyl-β-cyclodextrin. Drug Dev Ind Pharm. 2013;39:1638–1643.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SK, Ki MH, et al. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-β-cyclodextrin. Int J Pharm.2004;272:79–89.
   PubMed Web of Science ®Google Scholar
• Zuo Z, Tam YK, Diakur J, et al. Hydroxypropyl-betacyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat. J Pharm Pharm Sci. 2002;5:292–298.
   PubMed Web of Science ®Google Scholar
• Stella VJ, Rao VM, Zannou EA, et al. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev. 1999;36:3–16.
   PubMed Web of Science ®Google Scholar
• Yan Z, Xu W, Sun J, et al. Characterization and in vivo evaluation of an inclusion complex of oridonin and 2-hydroxypropyl-beta-cyclodextrin. Drug Dev Ind Pharm. 2008;34:632–641.
   PubMed Web of Science ®Google Scholar
• Bangphumi K, Kittiviriyakul C, Towiwat P, et al. Pharmacokinetics of curcumin diethyl disuccinate, a prodrug of curcumin, in wistar rats. Eur J Drug Metab Pharmacokinet. 2016; 41:777–785.
   PubMed Web of Science ®Google Scholar
• Fenyvesi F, Réti-Nagy K, Bacsó Z, et al. Fluorescently labeled methyl-beta-cyclodextrin enters intestinal epithelial caco-2 cells by fluid-phase endocytosis. PLoS One. 2014; 9:e84856.
   PubMed Web of Science ®Google Scholar
• Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta. 2009;1788:892–910.
   PubMed Web of Science ®Google Scholar
• Gu F, Li W, Men G, et al. Pharmacokinetic study of norfloxaein-sulfobutylether-β-cyelodextrin complex in rat. Chin J Mod Appl Pharm. 2012;29:346–349.
   Google Scholar